BGIM
SWTX

Boussard & Gavaudan Investment Management’s SpringWorks Therapeutics SWTX Stock Holding History

Boussard & Gavaudan Investment Management’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-86,500
Closed -$3.87M – 68
2025
Q1 		$3.87M Buy
+86,500
New +$3.98M 0.61% 37

Other funds holding SWTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.28% 1-Year Est. Return

Boussard & Gavaudan Investment Management's SWTX Position: Q2 2025 in Review

Boussard & Gavaudan Investment Management sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 86,500 shares — an estimated $3.87M sold.

Boussard & Gavaudan Investment Management first reported a position in SWTX in Q1 2025 and held it in 1 quarter. The position peaked at $3.87M in Q1 2025. 222 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

  • Boussard & Gavaudan Investment Management reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Boussard & Gavaudan Investment Management sold 86,500 SpringWorks Therapeutics shares in Q2 2025, an estimated $3.87M.
  • Boussard & Gavaudan Investment Management first reported a position in SpringWorks Therapeutics in Q1 2025 and held it in 1 quarter.
  • Boussard & Gavaudan Investment Management's SpringWorks Therapeutics position peaked at $3.87M in Q1 2025.
  • 222 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on Boussard & Gavaudan Investment Management's 13F filing for Q2 2025, filed 15 Aug 2025.